Maritime Launch Services Inc. Issues Early Warning Report Filing Pursuant to National Instrument 62-103
COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics
U.S. C-Suite Optimistic for 2025, but U.S. Presidential Election, Global Events and Regulatory Environment Loom Large
A Phase 3 Ready DMD Gene Therapy, a Clinical Trial to Offset AAV Neutralizing Antibodies, and an AI Inspired New Generation of Capsids Highlight Genethon’s 2024 Fall Milestones
